Payment overview · 2025
General Payments
$1,070.69
31 reported records · 12 companies
Healthcare provider profile · identity verified
Bruce Edward Lessin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MCLEAN, VA · NPI 1003973165
Verified facts
What the public records show
CMS Open Payments records show Bruce Edward Lessin, M.D. received $1,070.69 in general payments during 2025 across 31 reported records.
Amgen Inc. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $243.11 | 22.7% | 6 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $208.37 | 19.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.47 | 14.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.53 | 13.0% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.56 | 10.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.94 | 6.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.80 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.42 | 3.5% | 2 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $21.20 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.53 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.05 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.71 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,070.69 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $219.47 | 5 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $208.37 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.47 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $130.83 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.69 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.69 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.34 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.56 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.42 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 111 |
| Ezetimibe | Ezetimibe | 351 | 102 |
| Montelukast Sodium | Montelukast Sodium | 247 | 83 |
| Ramipril | Ramipril | 219 | 67 |
| Synthroid | Levothyroxine Sodium | 146 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 46 |
| Irbesartan | Irbesartan | 135 | 40 |
| Simvastatin | Simvastatin | 129 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 40 |
| Metformin Hcl | Metformin Hcl | 125 | 33 |
| Trazodone Hcl | Trazodone Hcl | 118 | 37 |
| Losartan Potassium | Losartan Potassium | 109 | 31 |
| Lisinopril | Lisinopril | 94 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 30 |
| Alprazolam | Alprazolam | 85 | 26 |
| Allopurinol | Allopurinol | 83 | 30 |
| Eliquis | Apixaban | 80 | 27 |
| Finasteride | Finasteride | 78 | 24 |
| Furosemide | Furosemide | 75 | 25 |
| Jardiance | Empagliflozin | 74 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 16 |
| Myrbetriq | Mirabegron | 63 | 21 |
| Ozempic | Semaglutide | 59 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 58 | 14 |
| Gabapentin | Gabapentin | 54 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 17 |
| Sertraline Hcl | Sertraline Hcl | 50 | 15 |
| Famotidine | Famotidine | 48 | 17 |
| Carvedilol | Carvedilol | 47 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 13 |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 20 |
| Potassium Chloride | Potassium Chloride | 40 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 34 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 27 |
| Valsartan | Valsartan | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 35 | 13 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 15 |
| Alendronate Sodium | Alendronate Sodium | 25 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Prednisone | Prednisone | 21 | 15 |
| Silodosin | Silodosin | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 11 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Prolia | Denosumab | 17 | 13 |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,070.69 · 31 records | Amgen Inc. | Cologuard Collection Kit, ELIQUIS, GEMTESA, INCEPTIV, JARDIANCE, JYNARQUE, KRYSTEXXA, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TARPEYO, The Cologuard Plus Collection Kit, ZEPBOUND, Zypitamag | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error